L-type calcium channel blockade on haloperidol-induced c-Fos expression in the striatum

Neuroscience

Volumn 149, Issue 3, 2007, Pages 602-616

  Lee, J ^a   Rushlow, W J ^a   Rajakumar, N ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

antipsychotic; catalepsy; CREB; dopamine; Elk 1; zif 268

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NIFEDIPINE; NIMODIPINE; RACLOPRIDE; TRANSCRIPTION FACTOR ELK 1;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; IMMEDIATE EARLY GENE; IMMUNOHISTOCHEMISTRY; MALE; NEOSTRIATUM; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; PSYCHOPHARMACOLOGY; RAT; WESTERN BLOTTING;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZAZEPINES; BLOTTING, WESTERN; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CATALEPSY; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DOPAMINE ANTAGONISTS; ETS-DOMAIN PROTEIN ELK-1; GENE EXPRESSION; GENES, FOS; HALOPERIDOL; IMMUNOHISTOCHEMISTRY; MALE; NEOSTRIATUM; NIFEDIPINE; NIMODIPINE; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2;

EID: 35448954512     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2007.08.013     Document Type: Article

References (53)

1. Adermark L., and Lovinger D.M. Combined activation of L-type Ca2+ channels and synaptic transmission is sufficient to induce striatal long-term depression. J Neurosci 27 (2007) 6781-6787
2. Bading H., Ginty D.D., and Greenberg M.E. Regulation of gene expression in hippocampal neurons by distinct calcium singaling pathways. Science 260 (1993) 181-186
3. Belforte J.E., Magarinos-Azcone C., Armando I., Buno W., and Pazo J.H. Pharmacological involvement of the calcium channel blocker flunarizine in dopamine transmission at the striatum. Parkinsonism Relat Disord 8 (2001) 33-40
4. Boegman R.J., and Vincent S.R. Involvement of adenosine and glutamate receptors in the induction of c-fos in the striatum by haloperidol. Synapse 22 (1996) 70-77
5. Bouchenafa O., and Littleton J.M. Expression of c-Fos protein immunoreactivity in rat brain during ethanol withdrawal is prevented by nifedipine. Alcohol 15 (1998) 71-76
6. Brindle P.K., and Montminy M.R. The CREB family of transcription activators. Curr Opin Genet Dev 2 (1992) 199-204
7. Calabresi P., Picconi B., Tozzi A., and Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trend Neurosci 30 (2007) 211-219
8. Catterall W.A., and Striessnig J. Receptor sites for Ca2+ channel antagonists. Trends Pharmacol Sci 13 (1992) 256-262
9. Chartoff E.H., Ward R.P., and Dorsa D.M. Role of adenosine and N-methyl-d-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy. J Pharmacol Exp Ther 291 (1999) 531-537
10. Degos B., Deniau J.M., Thierry A.M., Glowinski J., Pezard L., and Maurice N. Neuroleptic-induced catalepsy: electrophysiological mechanisms of functional recovery induced by high-frequency stimulation of the subthalamic nucleus. J Neurosci 25 (2005) 7687-7696
11. Deutch A.Y., Lee M.C., and Iadarola M.J. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 3 (1992) 332-341
12. Doucet J.P., Nakabeppu Y., Bedard P.J., Hope B.T., Nestler E.J., Jasmin B.J., Chen J.S., Iadarola M.J., St-Jean M., Wigle N., Blanchet P., and Robertson G.S. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci 8 (1996) 365-381
13. Dragunow M., Robertson G.S., Faull R.L., Robertson H.A., and Jansen K. DA dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience 37 (1990) 287-294
14. 2+ accumulation when dopamine receptors are activated in striatal neurons. Mol Brain Res 131 (2004) 65-72
15. Goto S., Matsukado Y., Miyamoto E., and Yamada M. Morphological characterization of the rat striatal neurons expressing calcineurin immunoreactivity. Neuroscience 22 (1987) 189-201
16. Greengard P., Allen P.B., and Nairn A.C. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23 (1999) 435-447
17. Hauber W., and Munkle M. Stimulation of adenosine 2a receptors in the rat striatum induces catalepsy that is reversed by antagonists of N-methyl-d-aspartate receptors. Neurosci Lett 196 (1995) 205-208
18. Hernandez-Echeagaray E., Starling A.J., Cepeda C., and Levine M.S. Modulation of AMPA currents by D2 dopamine receptors in striatal medium-spiny neurons: are dendrites necessary?. Eur J Neurosci 19 (2004) 2455-2463
19. Hernandez-Lopez S., Tkatch T., Perez-Garci E., Galarraga E., Bargas J., Hamm H., and Surmeier D.J. D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PCLb1-IP3 calcineurin-signaling cascade. J Neurosci 20 (2000) 8987-8995
20. Hoffman D.C., and Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology 120 (1995) 128-133
21. Hussain N., Flummerfelt B.A., and Rajakumar N. Glutamatergic regulation of haloperidol-induced c-fos expression in the rat striatum and nucleus accumbens. Neuroscience 102 (2001) 391-399
22. Hussain N., Flumerfelt B.A., and Rajakumar N. Role of muscarinic, adenosine A2 and histamine H3 receptors in haloperidol-induced c-fos expression in the striatum and nucleus accumbens. Neuroscience 112 (2002) 427-438
23. Johnson C., Hill C., Chawala S., Treisman R., and Bading H. Calcium controls gene expression via three distinct pathways that can function independently of the ras/mitogen-activated protein kinases (ERKs) signaling cascade. J Neurosci 17 (1997) 6189-6202
24. Kapur S., Zipursky R., Jones C., Remington G., and Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first episode schizophrenia. Am J Psychiatry 157 (2000) 514-520
25. Keefe K.A., and Adams A.C. Differential effects of N-methyl-d-aspartate receptor blockade on eticlopride-induced immediate early gene expression in the medial and lateral striatum. J Pharmacol Exp Ther 287 (1998) 1076-1083
26. Kitamura N., Ohta T., Ito S., and Nakazato Y. Effects of nifedipine and Bay K 8644 on contractile activities in single skeletal muscle fibers of the frog. Eur J Pharmacol 256 (1994) 169-176
27. Konradi C., Leveque J.C., and Hyman S.E. Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends upon postsynaptic NMDA receptors and calcium. J Neurosci 16 (1996) 4231-4239
28. Langley K.C., Bergson C., Greengard P., and Ouimet C.C. Co-localization of the D1 dopamine receptor in a subset of DARPP-32-containing neurons in rat caudate-putamen. Neuroscience 78 (1997) 977-983
29. Mao L., and Wang J.Q. Group I metabotropic glutamate receptor-mediated calcium signaling and immediate early gene expression in cultured rat striatal neurons. Eur J Neurosci 17 (2003) 741-750
30. Marais R., Wynne J., and Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 73 (1993) 381-393
31. Marchese G., Bartholini F., Ruiu S., Casti P., Saba P., Gessa G., and Pani L. Effects of amisulpride isomers on rat catalepsy. Eur J Pharmacol 444 (2002) 69-74
32. Marin C., Bonastre M., and Tolosa E. Striatal c-fos levels do not correlate with haloperido-induced behavioral supersensitivity. Synapse 23 (1996) 89-93
33. Merchant K.M., and Dorsa D.M. Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc Natl Acad Sci U S A 90 (1993) 3447-3451
34. Merchant K.M. C-fos antisense oligonucleotide specifically attenuates haloperidol-induced increases in neurotensin/neuromedin N mRNA expression in rat dorsal striatum. Mol Cell Neurosci 5 (1994) 336-344
35. Mishra R., Bonni A., Miranti C., Rivera V., Sheng M., and Greenberg M.E. L-type voltage-sensitive calcium channel activation stimulates gene expression by a serum response factor-dependent pathway. J Biol Chem 269 (1994) 25483-25493
36. O'Neill S.K., and Bolger G.T. Phecyclidine and MK801: a behavioral and neurochemical comparison of their interactions with dihydropyridine calcium antagonists. Brain Res Bull 22 (1989) 611-616
37. Osborne P.G., O'Connor W.T., Beck O., and Ungerstedt U. Acute versus chronic haloperidol: relationship between tolerance to catalepsy and striatal and accumbens dopamine, GABA and acetylcholine release. Brain Res 634 (1994) 20-30
38. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. Compact. 3rd ed. (1997), Academic Press, Sydney
39. Polli J., Billingsley L., and Kincaid R. Expression of the calmodulin-dependent protein phosphatase, calcineurin, in rat brain: developmental patterns and the role of nigrostriatal innervation. Dev Brain Res 63 (1991) 105-119
40. Rajadhyaksha A., Barczak A., Macias W., Leveque J.C., Lawis S.E., and Konradi C. L-type Ca2+ channels are essential for glutamate-mediated CREB phosphorylation and c-fos gene expression in striatal neurons. J Neurosci 19 (1999) 6348-6359
41. Robertson G.S., and Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 49 (1992) 285-296
42. Robertson G.S., Matsumura H., and Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271 (1994) 1058-1066
43. Rushlow W.J., Seah Y.H., Belliveau D.J., and Rajakumar N. Antipsychotics alter calcineurin mRNA, protein expression levels and phosphatase activity. J Neurochem 94 (2005) 587-596
44. Sheng M., Dougan S.T., McFadden G., and Greenberg M.E. Calcium and growth factor pathways of c-Fos transcriptional activation require distinct upstream regulatory sequences. Mol Cell Biol 8 (1988) 2787-2796
45. Snijders R., Kramarcy N.R., Hurd R.W., Nemeroff C.B., and Dunn A.J. Neurotensin induces catalepsy in mice. Neuropharmacology 21 (1982) 465-468
46. Sonnenberg J.L., Mitchelmore C., Macregor-Leon P.F., Hempstead J., Morgan J.L., and Curran T. Glutamate receptor agonists increase the expression of Fos, Fra, and AP-1 DNA binding activity in the mammalian brain. J Neurosci Res 24 (1989) 72-80
47. Sugimoto T., Stewart S., and Guan K. The calcium/calmodulin dependent protein phosphatase calcineurin is the major Elk-1 phosphatase. J Biol Chem 272 (1997) 29415-29418
48. Swanson T.H., and Green C.L. Nifedipine: more than a calcium blocker. Gen Pharmacol 17 (1986) 255-260
49. Wang Z., Kai L., Day M., Ronesi J., Yin H.H., Ding J., Tkatch T., Lovinger D.M., and Surmeier D.J. Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron 50 (2006) 443-452
50. White J.D., and Gall C.M. Differential regulation of neuropeptide and proto-oncogene mRNA content in the hippocampus following recurrent seizures. Brain Res 427 (1987) 21-29
51. White J.M., and Smith A.M. Modification of the behavioral effects of ethanol by nifedipine. Alcohol Alcoholism 27 (1992) 137-141
52. Xia Z., Dudek H., Miranti C.K., and Greenberg M.E. Calcium influx via the NMDA receptor induces immediate early gene transcription by a MAP kinase/ERK-dependent mechanism. J Neurosci 16 (1996) 5425-5436
53. Ziolkowska B., and Hollt V. The NMDA receptor antagonist MK-801 markedly reduces the induction of c-fos gene by haloperidol in the mouse striatum. Neurosci Lett 156 (1993) 39-42